Antipsychotic Risk Examined In NEJM; Did FDA Judge Atypicals Unfairly?
Executive Summary
Conventional antipsychotic medications should not be prescribed as replacements for atypical products despite an FDA public health advisory about the newer agents because conventional medications appear to have higher mortality in elderly patients, an article in the Dec. 1 New England Journal of Medicine concludes
You may also be interested in...
FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class
FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class
FDA Drug Risk Communication Should Include Drug Benefit Info, PhRMA Says
FDA risk communication materials should include information about a drug's benefits to avoid scaring patients away from their medications, the Pharmaceutical Research & Manufacturers of America said